Core Viewpoint - The stock of HBM Holdings (02142) rose over 5% following the announcement of presenting new clinical data at the upcoming ESMO annual meeting in Berlin [1] Group 1: Clinical Developments - HBM Holdings will present Phase II clinical data for its fully human anti-CTLA-4 antibody, HBM4003, in combination with Tislelizumab for microsatellite stable (MSS) metastatic colorectal cancer (mCRC) from October 17 to 21 [1] - The company has initiated a global development plan for HBM4003 targeting various solid tumors, utilizing an adaptive treatment design [1] Group 2: Strategic Partnerships - In June, HBM Holdings announced a collaboration with Otsuka Pharmaceutical to advance HBM7020 in the autoimmune field, with Otsuka acquiring rights outside Greater China [1] - Otsuka will pay a total of $47 million in upfront and milestone payments, with potential additional payments of up to $623 million based on future product net sales [1] - The rights for this drug in China were previously licensed to Huahai Biological (002007) in 2020 [1]

Core Viewpoint - The company will present Phase II clinical data for its novel fully human only heavy chain anti-CTLA-4 antibody, HBM4003, in combination with Tislelizumab for microsatellite stable metastatic colorectal cancer (mCRC) at the 2025 European Society for Medical Oncology (ESMO) annual meeting in Berlin from October 17 to October 21, 2025 [1] Group 1 - HBM4003 is developed from the HCAb Harbour Mice® platform and is the first fully human only heavy chain antibody to enter clinical stages globally [1] - Compared to traditional anti-CTLA-4 antibodies, HBM4003 shows significantly enhanced Treg cell clearance and optimized pharmacokinetics, contributing to improved safety [1] - HBM4003 enhances antibody-dependent cellular cytotoxicity (ADCC), increasing the potential for selective clearance of intratumoral Treg cells, which may overcome efficacy and toxicity limitations of existing CTLA-4 therapies [1] Group 2 - The company has initiated a global development plan for HBM4003 targeting various solid tumors, employing an adaptive treatment design [1] - Positive efficacy and safety data have been observed in clinical trials for advanced solid tumors, both as monotherapy and in combination with PD-1 inhibitors for melanoma, colorectal cancer, neuroendocrine cancer, and hepatocellular carcinoma [1]

Core Viewpoint - The company will present clinical data for its next-generation fully human anti-CTLA-4 antibody, HBM4003, in combination with Tislelizumab for the treatment of microsatellite stable (MSS) metastatic colorectal cancer (mCRC) at the 2025 European Society for Medical Oncology (ESMO) annual meeting in Berlin from October 17 to October 21, 2025 [1] Company Summary - The company is scheduled to announce its Phase II clinical data for HBM4003 during a significant oncology conference [1] - The focus of the clinical data presentation will be on the treatment of MSS mCRC, indicating the company's commitment to advancing cancer therapies [1] Industry Summary - The announcement aligns with ongoing developments in the oncology sector, particularly in the area of immunotherapy for colorectal cancer [1] - The ESMO annual meeting serves as a key platform for showcasing advancements in cancer treatment, highlighting the importance of such presentations for industry stakeholders [1]